ImmunoCellular Therapeutics (IMUC) Tops Q3 EPS by 2c

ImmunoCellular Therapeutics (NYSE: IMUC) reported Q3 EPS of ($0.04), $0.02 better than the analyst estimate of ($0.06).

For earnings history and earnings-related data on ImmunoCellular Therapeutics (IMUC) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• Archrock names Mohit Singh as CFO, effective July 6
• KB Home (KBH) PT Raised to $56 at Truist Securities